Cargando…

Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites

BACKGROUND: The alfapump(®) is an implantable class III medical device that pumps ascitic fluid from the peritoneal space to the urinary bladder from where it is excreted. The pump reduces or abrogates the need for repeated paracentesis in patients with recurrent or refractory ascites. AIMS: To impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aagaard, Niels Kristian, Malago, Massimo, De Gottardi, Andrea, Thomas, Michael, Sauter, Gerd, Engelmann, Cornelius, Aranovich, David, Cohen, Michal, Thévenot, Thierry, Ehmann, Thomas, Capel, Jeroen, Angeli, Paolo, Jalan, Rajiv, Stirnimann, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905806/ https://www.ncbi.nlm.nih.gov/pubmed/35260086 http://dx.doi.org/10.1186/s12876-022-02173-5

Ejemplares similares

Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites
por: Fotopoulou, Christina, et al.
Publicado: (2019)

Alfapump(® )implantable device in management of refractory ascites: An update
por: Weil-Verhoeven, Delphine, et al.
Publicado: (2022)

Radiological insertion of automated low flow ascitic pump (alfapump(®)) system for management of medically refractory ascites
por: Karkhanis, Salil, et al.
Publicado: (2017)

Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis
por: Stirnimann, G., et al.
Publicado: (2017)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump
por: Stirnimann, Guido, et al.
Publicado: (2022)

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

High mortality of pneumonia in cirrhotic patients with ascites
por: Hung, Tsung-Hsing, et al.
Publicado: (2013)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

Current approaches to the management of patients with cirrhotic ascites
por: Garbuzenko, Dmitry Victorovich, et al.
Publicado: (2019)

The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX(©) Catheter
por: Reinglas, Jason, et al.
Publicado: (2016)

The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive changes in Cirrhotic Patients with Ascites
por: Shahed, Forhad Hossain Md, et al.
Publicado: (2016)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Bacteriologic study of cirrhotic patients with non-neutrocytic ascites
por: Dabiri, Hossein, et al.
Publicado: (2014)

Alteration of the serum microbiome composition in cirrhotic patients with ascites
por: Santiago, Alba, et al.
Publicado: (2016)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Predictors of Spontaneous Bacterial Peritonitis in Patients with Cirrhotic Ascites
por: Metwally, Khaled, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Undifferentiated shock in a cirrhotic patient: Ascites matters
por: Xenou, Antigoni, et al.
Publicado: (2021)

A Smartphone App to Manage Cirrhotic Ascites Among Outpatients: Feasibility Study
por: Bloom, Patricia, et al.
Publicado: (2020)

The Role of Serum Procalcitonin Levels in Predicting Ascitic Fluid Infection in Hospitalized Cirrhotic and Non-cirrhotic Patients
por: Cekin, Yesim, et al.
Publicado: (2013)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving
por: Bloom, Patricia P., et al.
Publicado: (2021)

Ascitic Bacterial Composition Is Associated With Clinical Outcomes in Cirrhotic Patients With Culture-Negative and Non-neutrocytic Ascites
por: Chen, Yanfei, et al.
Publicado: (2018)

Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy
por: Thomsen, Karen Louise, et al.
Publicado: (2016)

Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global consensus?
por: Engelmann, Cornelius, et al.
Publicado: (2023)

Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites
por: Kalambokis, Georgios N., et al.
Publicado: (2011)

Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians
por: Gallo, Andrea, et al.
Publicado: (2020)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Serum and ascitic D-dimer in cirrhotic patients with spontaneous bacterial peritonitis
por: El Gohary, Ahmed M., et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats
por: Ying, Yi, et al.
Publicado: (2023)

Splanchnic and Systemic Hemodynamics in Cirrhotic Patients With Refractory Ascites. Effect of Peritoneovenous Shunting
por: Vons, Corinne, et al.
Publicado: (1991)

Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites
por: Minakari, Mohammad, et al.
Publicado: (2011)

Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis
por: Wallerstedt, Sven, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c4h2835ivenbndkje29agp6523